alendronate has been researched along with Hematochezia in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (14.29) | 18.2507 |
2000's | 3 (42.86) | 29.6817 |
2010's | 3 (42.86) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hou, MC; Hu, HY; Lee, FY; Lin, HC; Luo, JC; Peng, YL | 1 |
Connolly, JG; Gagne, JJ | 1 |
Brookhart, MA; Cadarette, SM; Katz, JN; Levin, R; Solomon, DH; Stedman, MR; Stürmer, T | 1 |
Katz, MH | 1 |
Nelson, DB; Sawhney, MS | 1 |
Kaye, PS | 1 |
Andrade, SE; Beck, A; Boles, M; Buist, DS; Carey, VJ; Chan, KA; Chandler, JM; Chase, GA; Donahue, JG; Ettinger, B; Fishman, P; Goodman, M; Guess, HA; Gurwitz, JH; LaCroix, AZ; Levin, TR; Platt, R | 1 |
7 other study(ies) available for alendronate and Hematochezia
Article | Year |
---|---|
Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: risk factor analysis from a nationwide population-based study.
Topics: Age Factors; Aged; Aged, 80 and over; Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bone Density Conservation Agents; Case-Control Studies; Comorbidity; Confounding Factors, Epidemiologic; Databases, Factual; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Osteoporosis; Risk Factors; Sex Factors; Taiwan | 2014 |
Comparison of Calipers for Matching on the Disease Risk Score.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Cardiovascular Diseases; Cohort Studies; Computer Simulation; Cyclooxygenase 2 Inhibitors; Epidemiologic Methods; Ezetimibe; Female; Gastrointestinal Hemorrhage; Humans; Male; Medicare; Models, Theoretical; Monte Carlo Method; Odds Ratio; Osteoporotic Fractures; Prognosis; Propensity Score; Raloxifene Hydrochloride; Risk Assessment; Simvastatin; United States | 2016 |
Comparative gastrointestinal safety of weekly oral bisphosphonates.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Epidemiologic Methods; Etidronic Acid; Female; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Hospitalization; Humans; Male; Osteoporosis; Pennsylvania; Risedronic Acid; Treatment Outcome | 2009 |
Opportunities to decrease inappropriate uses of proton pump inhibitors: Comment on "Proton pump inhibitor use and the antifracture efficacy of alendronate".
Topics: Alendronate; Bone Density Conservation Agents; Denmark; Dose-Response Relationship, Drug; Drug Interactions; Gastrointestinal Hemorrhage; Hip Fractures; Humans; Proton Pump Inhibitors; Risk | 2011 |
Alendronate-induced colon ulcers: case report of a new clinical entity.
Topics: Aged; Alendronate; Biopsy; Cecal Diseases; Cecum; Colon; Colonic Diseases; Colonoscopy; Diagnosis, Differential; Emergencies; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Osteitis Deformans | 2004 |
Gastric hemorrhage and ulceration in hiatal hernia sac associated with alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Esophageal Diseases; Female; Gastrointestinal Hemorrhage; Hernia, Hiatal; Humans; Ulcer | 1999 |
Gastric and duodenal safety of daily alendronate.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Cohort Studies; Duodenal Diseases; Duodenal Ulcer; Female; Gastrointestinal Hemorrhage; Hospitalization; Humans; Intestinal Perforation; Male; Middle Aged; Retrospective Studies; Risk Assessment; Stomach Ulcer | 2002 |